1. A New Era for NOACs:

3. Program Goals

4. Evidence For NOACs in Patients With NVAF-PCI

5. PIONEER AF-PCI Study Design

6. PIONEER AF-PCI Clinically Significant Bleeding

7. Assessing Competing Risks

8. RE-DUAL-PCI Trial Design

9. RE-DUAL-PCI Primary Endpoint: ISTH Major or CRNM Bleeding Event

10. RE-DUAL-PCI: Efficacy End Points

11. Choosing The Right Dose

12. AUGUSTUS Trial Study Design

13. COMPASS Trial Study Design

14. COMPASS Trial Baseline Characteristics

15. COMPASS -- Primary Endpoint* Rivaroxaban Plus Aspirin vs Aspirin Alone

16. COMPASS Trial Efficacy Outcomes

17. COMPASS Trial Major Bleeding

18. COMPASS Trial Net Clinical Benefit

19. COMPASS Trial: Cumulative Incidence of Primary Efficacy Outcome

20. COMPASS Trial Subgroup Analysis

21. NOAC Trials in Process

22. COMMANDER HF Rivaroxaban in HF

23. NOAC Trials in Process: Unresolved Issues in Established Indications

24. NOAC Trials in Process: Potential New Indications

25. Concluding Remarks

26. Abbreviations

27. Abbreviations (cont)